The Danish drugmaker said in November it would halt U.S. sales of Levemir by the end of 2024. Many health plans no longer cover the drug, which went off patent in 2019, and there are other options for patients on the market, Novo said.
from Health News | Latest Healthcare Sector & Healthcare Industry news, Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/Nly65aO
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment